---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-056253"
form_type: "8-K"
ticker: "GLUE"
cik: "0001826457"
company_name: "Monte Rosa Therapeutics, Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T06:54:03.821134+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Monte Rosa Q1 net loss $32M; pipeline advances with MRT-2359, MRT-6160, MRT-8102 milestones

## Summary
- Q1 2024 net loss $32.0M; cash $197.8M (down from $237.0M Dec 2023), sufficient into H1 2026.
- MRT-2359: RP2D determination expected Q2 2024, Phase 1 clinical data H2 2024, Phase 2 before year-end.
- MRT-6160: IND submission Q2 2024, Phase 1 SAD/MAD study mid-2024, data Q1 2025; favorable GLP tox profile.
- MRT-8102: NEK7-directed MGD shows CNS exposure in NHPs; IND on track for Q1 2025.
- New CCNE1-directed MGD discovery program launched for previously undruggable oncology target.

## SEC filing metadata
- accession: 0000950170-24-056253
- form_type: 8-K
- ticker: GLUE
- cik: 0001826457
- company_name: Monte Rosa Therapeutics, Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826457/000095017024056253/0000950170-24-056253-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826457/000095017024056253/glue-20240509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-056253
- JSON: https://secwatch.observer/filing/0000950170-24-056253.json
- Plain text: https://secwatch.observer/filing/0000950170-24-056253.txt

## Key facts
- Earnings Releases
  Monte Rosa Therapeutics, Inc. reported financial results for the first quarter ending March 31, 2024.
  - Period: the first quarter ending March 31, 2024
  - Result: reported results
  source text: Monte Rosa Therapeutics, Inc. (the "Company") announced its financial results for the quarter ended March 31, 2024. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1826457/000095017024056253/0000950170-24-056253-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.